RAD21 mutations in acute myeloid leukemia

Area of Science:

• Molecular Biology
• Hematology
• Oncology

Background:

• The cohesin complex plays a crucial role in DNA repair and chromosome segregation.
• Genomic alterations in cohesin complex members, particularly STAG2, are early events in acute myeloid leukemia (AML) development.
• The role of mutations in other cohesin members, like RAD21, in myeloid neoplasia remains unclear.

Purpose of the Study:

• To investigate the frequency, mutational profile, clinico-pathologic features, and prognostic impact of RAD21 mutations in AML.
• To provide insights into the genomic landscape of RAD21-mutated AML.
• To assess the potential independent prognostic significance of RAD21 mutations in AML.

Main Methods:

• Retrospective analysis of molecular profiles from 1,381 AML patients.
• Identification and characterization of 14 patients with RAD21 mutations.
• Evaluation of clinico-pathologic features and outcomes associated with RAD21 mutations.

Main Results:

• RAD21 mutations were identified in 14 out of 1,381 AML patients.
• RAD21-mutated AML frequently presented with monocytic differentiation and CD7 expression.
• Associated features included co-existing mutations in epigenetic regulators, a normal karyotype, and a poor prognosis.

Conclusions:

• RAD21 mutations are associated with a distinct morphologic, immunophenotypic, and genomic profile in AML.
• These findings suggest RAD21 mutations may hold independent prognostic significance in AML.
• Further evaluation of RAD21 mutations is warranted for risk stratification in AML patients.